Loading…
Pharmacy and therapeutics committees strategy to address olmesartan safety issues at a primary care level
Background Olmesartan, an antihypertensive drug, has been associated with a severe and potentially life-threatening sprue-like enteropathy, consisting of a serious, chronic diarrhoea and malabsorption syndrome. Treatment with this drug should be discontinued if patients develop such symptoms. Object...
Saved in:
| Published in: | International journal of clinical pharmacy 2020-04, Vol.42 (2), p.737-743 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c326t-de024e62991a73a04b17a5d7e8ad4c799f0fc975fd4d23582a8f69717a9a3b0b3 |
| container_end_page | 743 |
| container_issue | 2 |
| container_start_page | 737 |
| container_title | International journal of clinical pharmacy |
| container_volume | 42 |
| creator | Rovira-Illamola, Marina Pagès-Puigdemont, Neus Sotoca-Momblona, Josep Miquel Mensa-Vendrell, Mireia Barba-Ávila, Olga Casasayas-Guilera, Mercè |
| description | Background
Olmesartan, an antihypertensive drug, has been associated with a severe and potentially life-threatening sprue-like enteropathy, consisting of a serious, chronic diarrhoea and malabsorption syndrome. Treatment with this drug should be discontinued if patients develop such symptoms.
Objective
To retrospectively determine the reduction in olmesartan prescription following a strategy promoted by pharmacy and therapeutics committees within daily clinical practice to manage updated safety information on olmesartan.
Setting
Three primary healthcare centres.
Method
In May 2016, local pharmacy and therapeutics committees integrated by general practitioners, nursing staff and clinical pharmacists sent information about olmesartan safety issues to general practitioners, together with an individual list of their patients who were then being treated with olmesartan. Moreover, information about dose equivalents between angiotensin II receptor blockers and angiotensin II receptor blockers versus angiotensin-converting-enzyme inhibitors was also attached. The strategy aimed to promote individual benefit/risk assessment by general practitioners of the continuation of olmesartan treatment as a means to achieving a decrease in the risk of sprue-like enteropathy. The investigation team retrospectively reviewed the clinical records.
Main outcome measure
Reduction of olmesartan prescription.
Results
Olmesartan was discontinued in 44.4% of patients (197/444) in the year after the safety alert e-mail. In their medical records general practitioners registered that, after informing about olmesartan safety warnings, in four cases (0.9%), patients reported gastrointestinal symptoms.
Conclusion
A multidisciplinary strategy implemented to promote individual benefit/risk assessment regarding continuation of olmesartan treatment showed an important reduction in olmesartan prescriptions 1 year later. |
| doi_str_mv | 10.1007/s11096-020-00993-7 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_s11096_020_00993_7</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2396573501</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-de024e62991a73a04b17a5d7e8ad4c799f0fc975fd4d23582a8f69717a9a3b0b3</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMottT-AQ8S8Lw6SXY3zVGKX1DQg57DdDPbbul2a5IV-u-Nttabc8lAnnlneBi7FHAjAPRtEAJMmYGEDMAYlekTNpRSQKa1EKfHHtSAjUNYQaq8lKLIz9lASdATAXrImtcl-harHceN43FJHrfUx6YKvOratomRKPAQPUZa7HjsODrnKQTerVsK6CNueMCa4o43IfQJxsiRb33Tot_xCj3xNX3S-oKd1bgOND68I_b-cP82fcpmL4_P07tZVilZxswRyJxKaYxArRDyudBYOE0TdHmljamhrowuapc7qYqJxEldGp0gg2oOczVi1_vcre8-0j3Rrrreb9JKK5UpC60KEImSe6ryXQieanu42Aqw34LtXrBNgu2PYKvT0NUhup-35I4jvzoToPZASF-bBfm_3f_EfgFMfIcQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2396573501</pqid></control><display><type>article</type><title>Pharmacy and therapeutics committees strategy to address olmesartan safety issues at a primary care level</title><source>Springer Nature</source><creator>Rovira-Illamola, Marina ; Pagès-Puigdemont, Neus ; Sotoca-Momblona, Josep Miquel ; Mensa-Vendrell, Mireia ; Barba-Ávila, Olga ; Casasayas-Guilera, Mercè</creator><creatorcontrib>Rovira-Illamola, Marina ; Pagès-Puigdemont, Neus ; Sotoca-Momblona, Josep Miquel ; Mensa-Vendrell, Mireia ; Barba-Ávila, Olga ; Casasayas-Guilera, Mercè</creatorcontrib><description>Background
Olmesartan, an antihypertensive drug, has been associated with a severe and potentially life-threatening sprue-like enteropathy, consisting of a serious, chronic diarrhoea and malabsorption syndrome. Treatment with this drug should be discontinued if patients develop such symptoms.
Objective
To retrospectively determine the reduction in olmesartan prescription following a strategy promoted by pharmacy and therapeutics committees within daily clinical practice to manage updated safety information on olmesartan.
Setting
Three primary healthcare centres.
Method
In May 2016, local pharmacy and therapeutics committees integrated by general practitioners, nursing staff and clinical pharmacists sent information about olmesartan safety issues to general practitioners, together with an individual list of their patients who were then being treated with olmesartan. Moreover, information about dose equivalents between angiotensin II receptor blockers and angiotensin II receptor blockers versus angiotensin-converting-enzyme inhibitors was also attached. The strategy aimed to promote individual benefit/risk assessment by general practitioners of the continuation of olmesartan treatment as a means to achieving a decrease in the risk of sprue-like enteropathy. The investigation team retrospectively reviewed the clinical records.
Main outcome measure
Reduction of olmesartan prescription.
Results
Olmesartan was discontinued in 44.4% of patients (197/444) in the year after the safety alert e-mail. In their medical records general practitioners registered that, after informing about olmesartan safety warnings, in four cases (0.9%), patients reported gastrointestinal symptoms.
Conclusion
A multidisciplinary strategy implemented to promote individual benefit/risk assessment regarding continuation of olmesartan treatment showed an important reduction in olmesartan prescriptions 1 year later.</description><identifier>ISSN: 2210-7703</identifier><identifier>EISSN: 2210-7711</identifier><identifier>DOI: 10.1007/s11096-020-00993-7</identifier><identifier>PMID: 32078107</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Aged ; Aged, 80 and over ; Angiotensin ; Angiotensin II ; Angiotensin Receptor Antagonists - adverse effects ; Antihypertensive Agents - adverse effects ; Antihypertensives ; Celiac Disease - chemically induced ; Celiac Disease - epidemiology ; Diarrhea ; Drug Prescriptions - standards ; Drug stores ; Female ; Humans ; Imidazoles - adverse effects ; Internal Medicine ; Malabsorption ; Malabsorption Syndromes - chemically induced ; Malabsorption Syndromes - epidemiology ; Male ; Medical records ; Medicine ; Medicine & Public Health ; Middle Aged ; Nursing ; Patients ; Peptidyl-dipeptidase A ; Pharmacists ; Pharmacy ; Pharmacy and Therapeutics Committee - standards ; Primary Health Care - methods ; Primary Health Care - standards ; Research Article ; Retrospective Studies ; Risk assessment ; Risk Factors ; Safety ; Sprue ; Tetrazoles - adverse effects</subject><ispartof>International journal of clinical pharmacy, 2020-04, Vol.42 (2), p.737-743</ispartof><rights>Springer Nature Switzerland AG 2020</rights><rights>Springer Nature Switzerland AG 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c326t-de024e62991a73a04b17a5d7e8ad4c799f0fc975fd4d23582a8f69717a9a3b0b3</cites><orcidid>0000-0001-5118-8603</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32078107$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rovira-Illamola, Marina</creatorcontrib><creatorcontrib>Pagès-Puigdemont, Neus</creatorcontrib><creatorcontrib>Sotoca-Momblona, Josep Miquel</creatorcontrib><creatorcontrib>Mensa-Vendrell, Mireia</creatorcontrib><creatorcontrib>Barba-Ávila, Olga</creatorcontrib><creatorcontrib>Casasayas-Guilera, Mercè</creatorcontrib><title>Pharmacy and therapeutics committees strategy to address olmesartan safety issues at a primary care level</title><title>International journal of clinical pharmacy</title><addtitle>Int J Clin Pharm</addtitle><addtitle>Int J Clin Pharm</addtitle><description>Background
Olmesartan, an antihypertensive drug, has been associated with a severe and potentially life-threatening sprue-like enteropathy, consisting of a serious, chronic diarrhoea and malabsorption syndrome. Treatment with this drug should be discontinued if patients develop such symptoms.
Objective
To retrospectively determine the reduction in olmesartan prescription following a strategy promoted by pharmacy and therapeutics committees within daily clinical practice to manage updated safety information on olmesartan.
Setting
Three primary healthcare centres.
Method
In May 2016, local pharmacy and therapeutics committees integrated by general practitioners, nursing staff and clinical pharmacists sent information about olmesartan safety issues to general practitioners, together with an individual list of their patients who were then being treated with olmesartan. Moreover, information about dose equivalents between angiotensin II receptor blockers and angiotensin II receptor blockers versus angiotensin-converting-enzyme inhibitors was also attached. The strategy aimed to promote individual benefit/risk assessment by general practitioners of the continuation of olmesartan treatment as a means to achieving a decrease in the risk of sprue-like enteropathy. The investigation team retrospectively reviewed the clinical records.
Main outcome measure
Reduction of olmesartan prescription.
Results
Olmesartan was discontinued in 44.4% of patients (197/444) in the year after the safety alert e-mail. In their medical records general practitioners registered that, after informing about olmesartan safety warnings, in four cases (0.9%), patients reported gastrointestinal symptoms.
Conclusion
A multidisciplinary strategy implemented to promote individual benefit/risk assessment regarding continuation of olmesartan treatment showed an important reduction in olmesartan prescriptions 1 year later.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Angiotensin</subject><subject>Angiotensin II</subject><subject>Angiotensin Receptor Antagonists - adverse effects</subject><subject>Antihypertensive Agents - adverse effects</subject><subject>Antihypertensives</subject><subject>Celiac Disease - chemically induced</subject><subject>Celiac Disease - epidemiology</subject><subject>Diarrhea</subject><subject>Drug Prescriptions - standards</subject><subject>Drug stores</subject><subject>Female</subject><subject>Humans</subject><subject>Imidazoles - adverse effects</subject><subject>Internal Medicine</subject><subject>Malabsorption</subject><subject>Malabsorption Syndromes - chemically induced</subject><subject>Malabsorption Syndromes - epidemiology</subject><subject>Male</subject><subject>Medical records</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Nursing</subject><subject>Patients</subject><subject>Peptidyl-dipeptidase A</subject><subject>Pharmacists</subject><subject>Pharmacy</subject><subject>Pharmacy and Therapeutics Committee - standards</subject><subject>Primary Health Care - methods</subject><subject>Primary Health Care - standards</subject><subject>Research Article</subject><subject>Retrospective Studies</subject><subject>Risk assessment</subject><subject>Risk Factors</subject><subject>Safety</subject><subject>Sprue</subject><subject>Tetrazoles - adverse effects</subject><issn>2210-7703</issn><issn>2210-7711</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LAzEQhoMottT-AQ8S8Lw6SXY3zVGKX1DQg57DdDPbbul2a5IV-u-Nttabc8lAnnlneBi7FHAjAPRtEAJMmYGEDMAYlekTNpRSQKa1EKfHHtSAjUNYQaq8lKLIz9lASdATAXrImtcl-harHceN43FJHrfUx6YKvOratomRKPAQPUZa7HjsODrnKQTerVsK6CNueMCa4o43IfQJxsiRb33Tot_xCj3xNX3S-oKd1bgOND68I_b-cP82fcpmL4_P07tZVilZxswRyJxKaYxArRDyudBYOE0TdHmljamhrowuapc7qYqJxEldGp0gg2oOczVi1_vcre8-0j3Rrrreb9JKK5UpC60KEImSe6ryXQieanu42Aqw34LtXrBNgu2PYKvT0NUhup-35I4jvzoToPZASF-bBfm_3f_EfgFMfIcQ</recordid><startdate>20200401</startdate><enddate>20200401</enddate><creator>Rovira-Illamola, Marina</creator><creator>Pagès-Puigdemont, Neus</creator><creator>Sotoca-Momblona, Josep Miquel</creator><creator>Mensa-Vendrell, Mireia</creator><creator>Barba-Ávila, Olga</creator><creator>Casasayas-Guilera, Mercè</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><orcidid>https://orcid.org/0000-0001-5118-8603</orcidid></search><sort><creationdate>20200401</creationdate><title>Pharmacy and therapeutics committees strategy to address olmesartan safety issues at a primary care level</title><author>Rovira-Illamola, Marina ; Pagès-Puigdemont, Neus ; Sotoca-Momblona, Josep Miquel ; Mensa-Vendrell, Mireia ; Barba-Ávila, Olga ; Casasayas-Guilera, Mercè</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-de024e62991a73a04b17a5d7e8ad4c799f0fc975fd4d23582a8f69717a9a3b0b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Angiotensin</topic><topic>Angiotensin II</topic><topic>Angiotensin Receptor Antagonists - adverse effects</topic><topic>Antihypertensive Agents - adverse effects</topic><topic>Antihypertensives</topic><topic>Celiac Disease - chemically induced</topic><topic>Celiac Disease - epidemiology</topic><topic>Diarrhea</topic><topic>Drug Prescriptions - standards</topic><topic>Drug stores</topic><topic>Female</topic><topic>Humans</topic><topic>Imidazoles - adverse effects</topic><topic>Internal Medicine</topic><topic>Malabsorption</topic><topic>Malabsorption Syndromes - chemically induced</topic><topic>Malabsorption Syndromes - epidemiology</topic><topic>Male</topic><topic>Medical records</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Nursing</topic><topic>Patients</topic><topic>Peptidyl-dipeptidase A</topic><topic>Pharmacists</topic><topic>Pharmacy</topic><topic>Pharmacy and Therapeutics Committee - standards</topic><topic>Primary Health Care - methods</topic><topic>Primary Health Care - standards</topic><topic>Research Article</topic><topic>Retrospective Studies</topic><topic>Risk assessment</topic><topic>Risk Factors</topic><topic>Safety</topic><topic>Sprue</topic><topic>Tetrazoles - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rovira-Illamola, Marina</creatorcontrib><creatorcontrib>Pagès-Puigdemont, Neus</creatorcontrib><creatorcontrib>Sotoca-Momblona, Josep Miquel</creatorcontrib><creatorcontrib>Mensa-Vendrell, Mireia</creatorcontrib><creatorcontrib>Barba-Ávila, Olga</creatorcontrib><creatorcontrib>Casasayas-Guilera, Mercè</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection (ProQuest Medical & Health Databases)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>International journal of clinical pharmacy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rovira-Illamola, Marina</au><au>Pagès-Puigdemont, Neus</au><au>Sotoca-Momblona, Josep Miquel</au><au>Mensa-Vendrell, Mireia</au><au>Barba-Ávila, Olga</au><au>Casasayas-Guilera, Mercè</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacy and therapeutics committees strategy to address olmesartan safety issues at a primary care level</atitle><jtitle>International journal of clinical pharmacy</jtitle><stitle>Int J Clin Pharm</stitle><addtitle>Int J Clin Pharm</addtitle><date>2020-04-01</date><risdate>2020</risdate><volume>42</volume><issue>2</issue><spage>737</spage><epage>743</epage><pages>737-743</pages><issn>2210-7703</issn><eissn>2210-7711</eissn><abstract>Background
Olmesartan, an antihypertensive drug, has been associated with a severe and potentially life-threatening sprue-like enteropathy, consisting of a serious, chronic diarrhoea and malabsorption syndrome. Treatment with this drug should be discontinued if patients develop such symptoms.
Objective
To retrospectively determine the reduction in olmesartan prescription following a strategy promoted by pharmacy and therapeutics committees within daily clinical practice to manage updated safety information on olmesartan.
Setting
Three primary healthcare centres.
Method
In May 2016, local pharmacy and therapeutics committees integrated by general practitioners, nursing staff and clinical pharmacists sent information about olmesartan safety issues to general practitioners, together with an individual list of their patients who were then being treated with olmesartan. Moreover, information about dose equivalents between angiotensin II receptor blockers and angiotensin II receptor blockers versus angiotensin-converting-enzyme inhibitors was also attached. The strategy aimed to promote individual benefit/risk assessment by general practitioners of the continuation of olmesartan treatment as a means to achieving a decrease in the risk of sprue-like enteropathy. The investigation team retrospectively reviewed the clinical records.
Main outcome measure
Reduction of olmesartan prescription.
Results
Olmesartan was discontinued in 44.4% of patients (197/444) in the year after the safety alert e-mail. In their medical records general practitioners registered that, after informing about olmesartan safety warnings, in four cases (0.9%), patients reported gastrointestinal symptoms.
Conclusion
A multidisciplinary strategy implemented to promote individual benefit/risk assessment regarding continuation of olmesartan treatment showed an important reduction in olmesartan prescriptions 1 year later.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>32078107</pmid><doi>10.1007/s11096-020-00993-7</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-5118-8603</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2210-7703 |
| ispartof | International journal of clinical pharmacy, 2020-04, Vol.42 (2), p.737-743 |
| issn | 2210-7703 2210-7711 |
| language | eng |
| recordid | cdi_crossref_primary_10_1007_s11096_020_00993_7 |
| source | Springer Nature |
| subjects | Aged Aged, 80 and over Angiotensin Angiotensin II Angiotensin Receptor Antagonists - adverse effects Antihypertensive Agents - adverse effects Antihypertensives Celiac Disease - chemically induced Celiac Disease - epidemiology Diarrhea Drug Prescriptions - standards Drug stores Female Humans Imidazoles - adverse effects Internal Medicine Malabsorption Malabsorption Syndromes - chemically induced Malabsorption Syndromes - epidemiology Male Medical records Medicine Medicine & Public Health Middle Aged Nursing Patients Peptidyl-dipeptidase A Pharmacists Pharmacy Pharmacy and Therapeutics Committee - standards Primary Health Care - methods Primary Health Care - standards Research Article Retrospective Studies Risk assessment Risk Factors Safety Sprue Tetrazoles - adverse effects |
| title | Pharmacy and therapeutics committees strategy to address olmesartan safety issues at a primary care level |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T07%3A49%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacy%20and%20therapeutics%20committees%20strategy%20to%20address%20olmesartan%20safety%20issues%20at%20a%20primary%20care%20level&rft.jtitle=International%20journal%20of%20clinical%20pharmacy&rft.au=Rovira-Illamola,%20Marina&rft.date=2020-04-01&rft.volume=42&rft.issue=2&rft.spage=737&rft.epage=743&rft.pages=737-743&rft.issn=2210-7703&rft.eissn=2210-7711&rft_id=info:doi/10.1007/s11096-020-00993-7&rft_dat=%3Cproquest_cross%3E2396573501%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c326t-de024e62991a73a04b17a5d7e8ad4c799f0fc975fd4d23582a8f69717a9a3b0b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2396573501&rft_id=info:pmid/32078107&rfr_iscdi=true |